Publications by authors named "Zhongli Bao"
Article Synopsis
- A new synthetic version of glucagon for injection has been approved to treat severe hypoglycemia, and it is compared to the brand name recombinant glucagon.
- Two advanced methods (SEC-HPLC and FFF-MALS) were used to analyze the aggregation of both glucagon types across three new and three expired lots.
- Results showed comparable aggregation profiles, with only minimal dimer presence in expired lots, confirming both glucagon versions are physically stable and unlikely to aggregate in clinical use.
Article Synopsis
- Glucagon, a hormone important for treating low blood sugar, is unstable in water and can change its structure into potentially harmful forms.
- The study focused on analyzing the secondary structure of glucagon using techniques like circular dichroism spectroscopy and 2D Nuclear Overhauser effect spectroscopy at both release and expiry.
- Results showed consistent structure components across both synthetic and recombinant glucagon, indicating no significant differences in their stability over time.
Article Synopsis
- - Glucagon for Injection is a hormone medication used for treating severe low blood sugar, and a generic version was recently approved by the FDA, though it is made differently from the brand-name version.
- - The brand-name glucagon is made using recombinant DNA, while the generic version uses peptide synthesis, potentially affecting impurities that could trigger immune responses.
- - A study used specific cell lines to test the immune response to both glucagon versions and found that the generic glucagon had negligible immunogenicity risks, similar to the brand-name product.
